Singlet oxygen luminescence dosimetry (SOLD) for photodynamic therapy: current status, challenges and future
Mark T Jarvi1, Mark J Niedre, Michael S Patterson
1Department of Medical Biophysics, Ontario Cancer Institute and University of Toronto, Toronto, Ontario, Canada.
Abstract:
As photodynamic therapy (PDT) continues to develop and find new clinical indications, robust individualized dosimetry is warranted to achieve effective treatments. We posit that the most direct PDT dosimetry is achieved by monitoring singlet oxygen (1O2), the major cytotoxic species generated photochemically during PDT. Its detection and quantification during PDT have been long-term goals for PDT dosimetry and the development of techniques for this, based on detection of its near-infrared luminescence emission (1270 nm), is at a noteworthy stage of development. We begin by discussing the theory behind singlet-oxygen luminescence dosimetry (SOLD) and the seminal contributions that have brought SOLD to its current status. Subsequently, technology developments that could potentially improve SOLD are discussed, together with future areas of research, as well as the potential limitations of this method. We conclude by examining the major thrusts for future SOLD applications: as a tool for quantitative photobiological studies, a point of reference to evaluate other PDT dosimetry techniques, the optimal means to evaluate new photosensitizers and delivery methods and, potentially, a direct and robust clinical dosimetry system.
Insights
Monitoring singlet oxygen (1O2) via singlet-oxygen luminescence dosimetry (SOLD) offers direct photodynamic therapy (PDT) dosimetry. This technique is advancing for clinical use and research applications.
Area of Science:
- Biomedical Engineering
- Photochemistry
- Medical Physics
Background:
- Photodynamic therapy (PDT) requires precise dosimetry for effective clinical outcomes.
- Singlet oxygen (1O2) is the primary cytotoxic agent in PDT, making its direct measurement crucial.
- Current PDT dosimetry methods lack the precision needed for individualized treatments.
Purpose of the Study:
- To review the theory and development of singlet-oxygen luminescence dosimetry (SOLD).
- To explore technological advancements and future research directions for SOLD.
- To assess the potential of SOLD as a clinical dosimetry tool.
Main Methods:
- Discussion of the theoretical principles of singlet-oxygen luminescence.
- Review of technological developments for detecting 1O2 luminescence at 1270 nm.
- Analysis of SOLD's potential applications and limitations.
Main Results:
- SOLD is a promising technique for direct PDT dosimetry by monitoring 1O2.
- Significant progress has been made in developing SOLD technology.
- Future applications include photobiology studies, dosimetry validation, and clinical dosimetry.
Conclusions:
- SOLD represents a significant advancement in PDT dosimetry.
- Further research and technological development can enhance SOLD's clinical utility.
- SOLD has the potential to become a robust system for real-time, individualized PDT dosimetry.
Related Concept Videos
01:23Photoluminescence: Fluorescence and Phosphorescence
A pair of electrons in a...
01:14Photoluminescence: Applications